study evaluating absorption, distribution, metabolism and excretion (ADME) of Single dose [14C] AZD2423 in Volunteers - ADME
Study identifier:D2600C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers
Medical condition
Neuroscience
Phase
-
Healthy volunteers
Yes
Study drug
AZD2423
Sex
Male
Actual Enrollment
6
Study type
Observational
Age
50 Years - 65 Years
Date
Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Single cohort of 6 subjects | Drug: AZD2423 AZD2423 |
Contacts
Investigators
Principal Investigator
Biljana Lilja
Astrazeneca
